Boe Technology Group Co., Ltd.

Hefei Xinsheng Optoelectronics Technology Co., Ltd.

Beijing University of Chemical Tehcnology

Beijing Bohua Xinzhi Technology Co., Ltd.

Biomedical Analysis Center of Academy of Military Medical Sciences

Beijing Bohua Xinzhi Technology, Inc.

Xin Pan

Haifeng Wang

Han Zhang

Tao Zhou

Huiyan Li

Xingfeng Ren

Hui Gao

Xuemin Zhang

Hai-Qi Wu

Yanrong Feng

Zhi-Nong Jiang

Haiqi Wu

Jin-Ji Gao

Ailing Li

An electromagnetic automatic balancing device based on radial excitation includes a shell, a rotatory ring, a stationary ring, a pair of connecting bearings and a controller. The rotatory ring includes two bilaterally symmetrical outer excitation magnetic rings, two bilaterally symmetrical inner excitation magnetic rings, two bilaterally symmetrical counterweight discs, two bilaterally symmetrical first counterweight blocks, two bilaterally symmetrical second counterweight blocks and a pair of rotatory-ring bearings. The stationary ring includes a stator, two bilaterally symmetrical excitation frameworks and two bilaterally symmetrical coils. The rotatory ring and the stationary ring are installed in the shell and connected through a pair of connecting bearings. The stator is installed in the center of the shell. The excitation frameworks are respectively fixed at both ends of the stator.

Electromagnetic automatic balancing device based on radial excitation

A mother substrate and a display panel are disclosed. The mother substrate includes a plurality of display panels, a plurality of first test terminals and a plurality of first one-way conductive circuits. Each of the display panels has a display area, and includes a plurality of first signal lines extending from outside of the display area to the display area in parallel; the plurality of first signal lines of each of the display panels are respectively electrically connected to one of the plurality of first test terminals; the plurality of first one-way conductive circuits are respectively electrically connected to the plurality of first signal lines outside the display area and are configured to allow signals to be able to transmit only from the plurality of first test terminals to the plurality of first signal lines of each of the display panels.

Mother substrate and display panel

A pneumatic liquid on-line automatic balancer of a rotor includes: a sealed balancing disk rotating with a balanced rotor and a pressure transfer device mated with the sealed balancing disk. At least two pairs of centrosymmetric chambers filled with appropriate balancing liquid are evenly distributed in the sealed balancing disk. The pressure transfer device controls compressed gas in and out of the chamber and makes the balancing liquid controllably flow in each pair of chambers to achieve dynamic balance of the rotor. A communicating channel of the balancing liquid is provided between each pair of the chambers. The communicating channel of the balancing liquid is one and a center of the communicating channel of the balancing liquid is communicated with the balancing channel pointed to a center of rotation. The balancing channel is communicated with an emptying channel opened to atmosphere.

Pneumatic liquid on-line automatic balancer of rotor

Disclosed is a use of the CUEDC2 protein in the preparation of diagnostic agents for prognostic determination of the endocrinology therapy for the breast cancer patients and for the diagnosis of tumor such as breast cancer and ovarian cancer. The diagnostic agent comprises an antibody against the CUEDC2 protein, wherein the antibody is a monoclonal or polyclonal antibody against the CUEDC2 protein. Provided is a kit or a composition for prognostic determination of endocrinology therapy for the breast cancer patients and for the diagnosis of tumors such as breast cancer and ovarian cancer. The kit or composition comprises an antibody against the CUEDC2 protein. Further disclosed is a use of the CUEDC2 gene or protein in preparation of drugs for treating tumors, that is, small molecular substances and specific antibodies that specifically inhibit the expression or activity of the CUEDC2 gene\protein are used as a therapeutic agent to restore the sensitivity of drug-resistant tumors to drug treatment. The new use of the CUEDC2 protein provides a new basis for determining a dosage regimen of adjuvant therapy after surgical operation of the breast cancer patients, thereby improving the therapeutic effect of the anti-cancer drugs and alleviating the suffering and economic burden of the patients.

Molecular marker CUEDC2 protein for prognostic determination of breast cancer endocrinology therapy

Growing community of inventors

Beijing, China

Xin Pan